Candel Therapeutics (CADL) Total Debt (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Total Debt data on file, last reported at $1.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Debt fell 91.33% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (down 91.33% YoY), and the FY2025 full-year result was $1.0 million, down 91.33% from the prior year.
• Total Debt eased to $1.0 million in Q4 2025, from $5.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $20.4 million in Q3 2023 to a low of $521000.0 in Q2 2021.
• A 5-year average of $10.4 million and a median of $10.1 million in 2025 frame the typical range for Total Debt.
• Across the five-year window, Total Debt soared 3743.76% in 2022 and plunged 91.33% in 2025, its largest moves.
• Tracing CADL's Total Debt over 5 years: stood at $560000.0 in 2021, then soared by 3507.5% to $20.2 million in 2022, then plunged by 52.26% to $9.6 million in 2023, then climbed by 20.57% to $11.6 million in 2024, then sank by 91.33% to $1.0 million in 2025.
• Business Quant data shows CADL's Total Debt at $1.0 million in Q4 2025, $5.2 million in Q3 2025, and $6.7 million in Q2 2025.